Paper Details

  1. Home
  2. Paper Details

Ozanimod for the treatment of relapsing forms of multiple sclerosis.

Author: KuczynskiAndrea M, OhJiwon

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ozanimod, a selective S1P receptor modulator, has been approved for treating relapsing multiple sclerosis. It offers potent efficacy and tolerability compared to fingolimod, the first oral S1P receptor modulator.
Paper Details　
Original Abstract of the Article :
Multiple sclerosis (MS) is an inflammatory disease that causes chronic neurological disability in young adults. Modulation of sphingosine 1-phosphate (S1P) receptors, a group of receptors that, among other things, regulate egression of lymphocytes from lymph nodes, has proven to be effective in trea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/nmt-2021-0005

データ提供：米国国立医学図書館（NLM）

Ozanimod for Relapsing Multiple Sclerosis

This review focuses on ozanimod, a selective sphingosine 1-phosphate (S1P) receptor modulator, which has recently been approved for the treatment of relapsing multiple sclerosis (MS). The review summarizes ozanimod’s mechanism of action, efficacy, and safety profile, highlighting its potential as a new treatment option for relapsing MS.

A New Hope for MS Patients

Ozanimod’s demonstrated efficacy and tolerability profile, coupled with its selective S1P receptor modulation, make it a promising new treatment option for relapsing MS. This development is a significant step forward in the battle against MS, providing a beacon of hope for patients seeking effective and safe therapies.

Navigating the MS Treatment Landscape

This review, like a compass guiding a traveler through a vast desert, provides valuable insights into the latest advancements in MS treatment. The approval of ozanimod marks a significant milestone, offering new hope for individuals seeking effective and safe therapies to manage their condition.

Dr.Camel's Conclusion

This review explores the exciting potential of ozanimod, a new treatment for relapsing multiple sclerosis. Like a desert oasis providing respite from the harsh environment, ozanimod offers hope for patients seeking effective and safe therapies to manage their condition.

Date :
  1. Date Completed 2021-11-15
  2. Date Revised 2021-11-15
Further Info :

Pubmed ID

34011158

DOI: Digital Object Identifier

10.2217/nmt-2021-0005

Related Literature

Article Analysis
・Side Effects of ozanimod
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.